Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-05-16 | Redeye | Redeye: GenovisQ1 2024 - Financials in line with expectations, strong outlook | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Genovis | Communiqué from Genovis AB (publ) Annual General Meeting May 15, 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Genovis | Kommuniké från Årsstämman i Genovis AB (publ) den 15 maj 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Genovis | Genovis AB: Interim Report January - March 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Genovis | Genovis AB: Kvartalsrapport januari - mars 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Genovis | Genovis AB: Genovis Annual Report 2023 published | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Genovis | Genovis AB: Genovis årsredovisning 2023 publicerad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-09 | Genovis | Genovis AB: KALLELSE TILL ÅRSSTÄMMA 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-09 | Genovis | Genovis AB: NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Genovis AB: NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETINGRight to participate. Registration Shareholders who are registered in the register of shareholders maintained by Euroclear Sweden AB on May 6, 2024, and who have notified the company of their intention to attend the Annual General Meeting by no later than May 8, 2024, preferably before 3:00 p.m., have the right to attend the Annual General Meeting. Notification may be made by mail at Genovis AB c/o Advokatfirman Källén AB, Stora Tomegatan 5, 223 51 Lund, or per Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to attend the meeting, request that their nominee re-register their shares in their own name, so that the shareholder is registered in the shareholder register on May 6, 2024. Such registration may be temporary (so-called ”voting right registration”) and is requested from the nominee in accordance with the nominee’s procedures at such time in advance as determined by the nominee. Voting rights registration that has been made by the nominee not later than Wednesday, May 8, 2024 will be taken into account in the preparation of the share register. Proxy Shareholders who are represented by proxy shall issue a written, signed and dated power of attorney for the proxy. Shareholders should submit the power of attorney together with the notification of their intention to participate at the AGM. The expiry date of the proxy document may be no more than five years from its issue. Proxy forms are available on the company’s website, https://investor.genovis.com/en/corporate-governance/general-meeting/ . Representatives of legal entities must present a copy of the certificate of registration or equivalent authorization documents showing the authorized signatory. Proposed Agenda 1. 2. 3. 4. 5. 6. 7. 8. 9. 1. 2. 3. 10. 11. 12. 13. 14. 15. 16. 17. 18. Item 2. Election of Chairman of the Meeting The Nomination Committee proposes that attorney Arne Källén chair the meeting. Item 10 Resolution regarding number of Board members and deputy members The Nomination Committee proposes that the Board shall consist of five members without deputies. Item 11 Determination of fees for members of the Board of Directors The Nomination Committee proposes that fees until the close of the next Annual General Meeting shall be paid in the amount of SEK 200,000 to each Board member who is not employed by the company and SEK 400,000 to the Chairman of the Board. Item 12. Election of Directors and Chairman of the Board. The Nomination Committee proposes: Item 13 Resolution on fees to auditors The Nomination Committee proposes that remuneration to the auditors shall be paid on approved account. Item 14 Election of auditor The Nomination Committee proposes re-election of registered auditing firm Öhrlings PricewaterhouseCoopers AB (”PWC”). PWC has announced that in the event that PWC is elected, Neda Feher will be appointed auditor in charge. Item 15 Appointment of members to the Nomination Committee and adoption of guidelines for the Nomination Committee The Nomination Committee proposes that remuneration will only be paid for direct costs associated with the assignment. Item 16 The Board’s proposal authorizing the Board of Directors to decide on the issuance of shares. shareholders, the subscription shall be market-based at the time of the issue resolution. For a valid resolution under this item, the Meeting’s resolution must be supported by shareholders representing at least two thirds of both the voting rights and the shares represented at the Meeting. Documents The annual report, audit report, articles of association, proxy form and the other proposals for motions will be available at the Company’s office at Karl Johans väg 104, Kävlinge, and on the Company’s website www.genovis.com as of April 24, 2024, and will be sent, upon request, to shareholders who provide their mailing address. Number of shares and votes At the time of issuance of this notice, the total number of shares and votes in the company is 65,465,714. Information at the Annual General Meeting Shareholders are reminded of their right to request information from the Board of Directors and the Chief Executive Officer pursuant to Chapter 7, sections 32 and 57 of the Swedish Companies Act. A request for such information shall be submitted in writing to Genovis AB, Attn: Legal, Box 4, 244 21 Kävlinge, Sweden or by e-mail to: Lund, April 2024 Genovis AB (publ) Board of Directors |
||||
2024-03-14 | Genovis | Genovis AB: Carthesian Therapeutics terminates Genovis Licence Agreement | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-14 | Genovis | Genovis AB: Cartesian Therapeutics säger upp licensavtal med Genovis | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-19 | Redeye | Redeye: Genovis Q4 2023 - Soft ending but promising start | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-15 | Genovis | Genovis AB: Bokslutskommuniké januari-december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-15 | Genovis | Genovis AB: Year-end report January-December 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-13 | Genovis | Genovis AB: Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-13 | Genovis | Genovis AB: Genovis erhåller 1 miljon USD i milstolpsersättning relaterat till utvecklingen av Xork™-enzymet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Genovis | Genovis AB byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Genovis | Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-16 | Redeye | Redeye: Genovis Q3 2023 - Solid growth and profitability, Xork timeline remains on track | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-15 | Genovis | Genovis AB: Delårsrapport januari-september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-15 | Genovis | Genovis AB: Interim Report January-September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-25 | Redeye | Redeye: Genovis Q2 2023 - Strong growth and expanding EBIT margin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Genovis | Genovis AB: Halvårsrapport januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Genovis | Genovis AB: Half-Yearly Report January-June 2023 | Rapporter | Ladda ner | Visa Stäng |
|